11 analysts have shared their evaluations of Bristol-Myers Squibb BMY during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 0 | 9 | 2 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 3 | 0 | 0 |
| 2M Ago | 0 | 0 | 2 | 1 | 0 |
| 3M Ago | 0 | 0 | 3 | 1 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $48.0, a high estimate of $59.00, and a low estimate of $41.00. This current average reflects an increase of 2.32% from the previous average price target of $46.91.
Decoding Analyst Ratings: A Detailed Look
The analysis of recent analyst actions sheds light on the perception of Bristol-Myers Squibb by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Steve Scala | TD Cowen | Raises | Hold | $59.00 | $53.00 |
| Evan Seigerman | BMO Capital | Raises | Market Perform | $53.00 | $48.00 |
| Evan Seigerman | BMO Capital | Maintains | Market Perform | $48.00 | $48.00 |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Neutral | $50.00 | $50.00 |
| Akash Tewari | Jefferies | Raises | Hold | $51.00 | $49.00 |
| Carter Gould | Barclays | Raises | Underweight | $42.00 | $41.00 |
| Steve Scala | TD Cowen | Raises | Hold | $53.00 | $45.00 |
| Carter Gould | Barclays | Maintains | Underweight | $41.00 | $41.00 |
| James Shin | Deutsche Bank | Lowers | Hold | $45.00 | $53.00 |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Neutral | $45.00 | $45.00 |
| Carter Gould | Barclays | Lowers | Equal-Weight | $41.00 | $43.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Bristol-Myers Squibb. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bristol-Myers Squibb compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Bristol-Myers Squibb's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Bristol-Myers Squibb's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Bristol-Myers Squibb analyst ratings.
About Bristol-Myers Squibb
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Key Indicators: Bristol-Myers Squibb's Financial Health
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Bristol-Myers Squibb showcased positive performance, achieving a revenue growth rate of 8.69% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 13.77%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Bristol-Myers Squibb's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 10.03%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Bristol-Myers Squibb's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.73%, the company showcases efficient use of assets and strong financial health.
Debt Management: Bristol-Myers Squibb's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 3.17.
How Are Analyst Ratings Determined?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
